Boehringer Ingelheim

Boehringer Ingelheim develops breakthrough therapies that improve the lives of humans and animals. As a research-driven biopharmaceutical leader, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 50,000 employees serve more than 130 markets in the three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In Norway, Boehringer Ingelheim employs 64 people. In 2021, Boehringer Ingelheim’s Norwegian Branch achieved a total net sales revenue of NOK 483,9 million.